Patients
NSCLC, non‐small cell lung cancer, inappropriate stage
MAY, DISEASE, NSCLC
Between May 2015 and May 2019, 81 patients were enrolled at 13 institutions in Japan and were randomly assigned to group A (40 patients) or group B (41 patients). One patient in group A was excluded from the efficacy analysis because their disease was at an inappropriate stage (stage IB), and 2 patients in group B were excluded from this analysis because of they received an EGFR inhibitor within 2 weeks of the study treatment, had elevated ALT, and had disease at an inappropriate stage (stage IIIA) (Figure CONSORT Diagram of the study participants. Three patients were excluded from the efficacy analysis. However, these patients received study treatment and were included in the safety analysis. NSCLC, non‐small cell lung cancer.Baseline demographic and clinical characteristics of the study patients.
Abbreviations: One patient was diagnosed as stage IB and excluded from efficacy analysis.